Clinical Characteristics And LDL-C Achievement Rates In 506 FH Patients From 4 Russian Lipid Clinics

Сусеков, А. В.; Meshkov, Aleksey; Korneva, Viktoria; Ершова, А. И.; Kuznetsova, T.; Константинов, В. О.; Rozkova, Tatiana

doi:10.1016/j.jacl.2016.03.070

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apheresis is available in some large cities but is not reimbursed. Few patients meet LDL-C goal [77]; in a study in 4 lipid clinics (> 500 FH patients -DLCN ≥8 with coronary heart disease) only 6.6% achieved an LDL-C < 1.8 mmol/L [78].…”

Section: Russiamentioning

confidence: 99%

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

et al. 2018

View full text Add to dashboard Cite

The EAS FHSC is an international initiative involving a network of investigators interested in FH from around 70 countries.• Information on FH prevalence is lacking in most countries; where available, data tend to align with contemporary estimates.• FH diagnosis and management varies widely across countries, with overall suboptimal identification and under-treatment.• In most countries diagnosis primarily relies on DLCN criteria, and less frequently on Simon Broom or MEDPED.• Therapy for FH is not universally reimbursed, and criteria vary across countries. Access to PCSK9i and apheresis is limited.

show abstract

Section: Russiamentioning

confidence: 99%

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…больных с гетерозиготной и около 140 пациентов с гомозиготной формой СГХС [11][12][13]. Литературные обзоры и клинические случаи лечения больных с СГХС нами опубликованы ранее [14][15][16][17][18]. Повышение уровня ХС ЛНП более 4,9 ммоль/л в сочетании с отягощенным семейным анамнезом по СС-заболеваниям (ССЗ) и ГХС, а также наличие клинических признаков СГЛП (ксантомы, ксателазмы, утолщение ахилловых сухожилий) позволяют заподозрить диагноз СГХС.…”

Section: статины в первичной профилактике ссзunclassified

Statins in certain patient populations: scientific evidence and algorithms for practicing physicians

Сусеков¹

2021

View full text Add to dashboard Cite

Treatment with 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) is the basis for primary and secondary prevention of atherosclerosis and is regulated by many international and Russian guidelines and consensus. Data from lipid-lowering studies with "hard" endpoints showed that combination therapy can also lead to a further reduction in cardiovascular (CV) risk with the achievement of very low levels of low-density lipoprotein cholesterol (0.5–1 mmol/L) without increasing the risk of side effects. Despite the scientific progress in this field, there are large barriers between the recommendations and the real clinical practice of using statins in our country. As before, even patients with a very high CV risk are prescribed low and medium doses of statins by doctors of various specialties; the possibilities of combination therapy are still poorly realized. This review will provide an analysis of the evidence base, as well as an attempt to harmonize recommendations, expert consensus on optimizing statin therapy in certain patient groups – in primary prevention (low/moderate CV risk), in patients with high/very high CV risk in patients with arterial hypertension and dyslipidemia, as well as in patients with confirmed familial hypercholesterolemia. This publication presents possible algorithms for the use of statins in these categories of patients, which, in the author's opinion, will be useful for practicing physicians in their day-to-day clinical practice. Keywords: low-density lipoprotein cholesterol, dyslipidemia, statins, algorithms, primary prevention, arterial hypertension, cardiovascular risk, familial hypercholesterolemia For citation: Susekov AV. Statins in certain patient populations: scientific evidence and algorithms for practicing physicians. Consilium Medicum. 2021; 23 (1): 52–60. DOI: 10.26442/20751753.2021.1.200626

show abstract

“…По данным зарубежной литературы, частота встречаемости го-СГХС в Европе примерно 1:640 000-1 000 000 [4], и при экстраполяции этих данных можно ожидать, что в большой европейской стране, такой как Германия (81 млн человек), проживает около сотни больных с го-СГХС, а в Российской Федерации с населением 145 млн человек таких тяжелых больных может оказаться порядка двух сотен. Можно предположить, что не более 1% случаев СГХС в РФ диагностировано, причем далеко не все из них получают адекватную гиполипидемическую терапию [5]. Атеросклеротическое поражение сердечно-сосудистой системы при го-СГХС, в отличие от гетерозиготной СГХС, часто развивается уже в детском возрасте.…”

Section: Introductionunclassified

Homozygous familial hypercholesterolemia: modern aspects of pathogenesis, diagnostics and treatment

et al. 2018

View full text Add to dashboard Cite

Homozygous familial hypercholesterolemia is a rare genetic disease featuring extremely high of low-density lipoprotein blood level, cutaneous and tendon xanthomas and accelerated atherosclerosis with often manifestions in the first 2 decades of life, resulting to premature death due to atherosclerosis-related diseases. Modern combined lipid-lowering therapy is able to increase life duration considerably for these patients.

show abstract

Clinical Characteristics And LDL-C Achievement Rates In 506 FH Patients From 4 Russian Lipid Clinics

Cited by 3 publications

References 0 publications

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Statins in certain patient populations: scientific evidence and algorithms for practicing physicians

Homozygous familial hypercholesterolemia: modern aspects of pathogenesis, diagnostics and treatment

Contact Info

Product

Resources

About